SCHEMBL5402564

SCHEMBL5402564

COc1ccccc1CCN(CCC(=O)O)C(=O)c1ccccc1-c1ccccc1C(=O)NCc1cccc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.53
CHRNA4 P43681 1/20 0.53
HPGD P15428 5/20 0.47
CACNA1B Q00975 1/20 0.46
APBA1 Q02410 1/20 0.46
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.44
RCE1 Q9Y256 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
CYP2C19 P33261 1/20 0.44
MCL1 Q07820 1/20 0.43
BAD Q92934 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
HDAC6 Q9UBN7 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401059 0.94 CHRNB2 (0.51) CHRNB2CHRNA4HPGDCACNA1BAPBA1
SCHEMBL5406006 0.92 TAS1R3 (0.49) CHRNB2CHRNA4HPGDALDH1A1KDM4E
SCHEMBL5397621 0.92 HPGD (0.57) HPGDALDH1A1KDM4ERCE1PKM
SCHEMBL5406086 0.91 CHRNB2 (0.52) CHRNB2CHRNA4HPGDALDH1A1KDM4E
SCHEMBL5403362 0.89 KMT2A (0.55) CHRNB2CHRNA4CYP1A2CYP3A4CYP2D6
SCHEMBL5403714 0.88 CHRNB2 (0.56) CHRNB2CHRNA4HPGDALDH1A1KDM4E
SCHEMBL5394527 0.88 HPGD (0.50) HPGDALDH1A1KDM4ERCE1PKM
SCHEMBL5402292 0.88 PTPN1 (0.52) CHRNB2CHRNA4HPGDCACNA1BAPBA1
SCHEMBL5395882 0.87 HPGD (0.49) HPGDALDH1A1KDM4ERCE1MAPT
SCHEMBL5406253 0.87 ALDH1A1 (0.49) HPGDALDH1A1KDM4ERCE1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB CHRNB2 857/4885CHRNA4 1750/4885HPGD 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.